XML 45 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Condensed Consolidated Balance Sheets of Accrued expense

Accrued expenses as presented in the Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023 consisted of the following (in thousands):

 

 

December 31, 2024

 

 

December 31, 2023

 

Compensation

$

10,217

 

 

$

5,237

 

Severance

 

1,236

 

 

 

2,283

 

Clinical study related costs

 

16,452

 

 

 

1,658

 

Facility related costs

 

369

 

 

 

693

 

Accrued legal costs

 

395

 

 

 

1,015

 

Manufacturing improvement costs

 

72

 

 

 

4,365

 

Accrued consulting and professional fees

 

557

 

 

 

878

 

Other accrued expenses

 

1,839

 

 

 

1,536

 

Total accrued expenses and other

$

31,137

 

 

$

17,665

 

Schedule of Estimated Useful Lives The estimated useful lives are as follows:

 

Buildings

25-30 years

Computer equipment and software

3-5 years

Furniture and equipment

5-7 years

Leasehold improvements

remainder of lease term

Schedule of Fixed Asset

Fixed assets consisted of the following (in thousands):

 

 

December 31, 2024

 

 

December 31, 2023

 

Land

$

1,405

 

 

$

3,067

 

Buildings

 

21,095

 

 

 

22,490

 

Leasehold improvements

 

21,822

 

 

 

10,950

 

Furniture and equipment

 

5,647

 

 

 

3,690

 

Computer equipment and software

 

838

 

 

 

847

 

Construction in progress

 

2,447

 

 

 

8,741

 

Less: accumulated depreciation

 

(11,032

)

 

 

(7,642

)

Total fixed assets, net

$

42,222

 

 

$

42,143